Prospective study of Type 2 diabetes mellitus, anti-diabetic drugs and risk of prostate cancer

International Journal of Cancer

Volumn 140, Issue 3, 2017, Pages 611-617

  Häggström, Christel ^a,b   Van Hemelrijck, Mieke ^c,d   Zethelius, Björn ^b,e   Robinson, David ^a   Grundmark, Birgitta ^e   Holmberg, Lars ^c,f   Gudbjörnsdottir, Soffia ^g   Garmo, Hans ^c,f   Stattin, Pär ^a,b  

^a UMEÅ UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d KAROLINSKA INSTITUTE   (Sweden)

^e MEDICAL PRODUCTS AGENCY   (Sweden)

^f Regional Cancer Center Uppsala Orebro   (Sweden)

^g SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

cohort study; metformin; prostate cancer; survival analysis; Type 2 diabetes mellitus

Indexed keywords

ANTIDIABETIC AGENT; INSULIN; METFORMIN; SULFONYLUREA DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER RISK; COHORT ANALYSIS; COMORBIDITY; DISEASE DURATION; DISEASE SEVERITY; HUMAN; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; PROSTATE HYPERTROPHY; SOCIOECONOMICS; SWEDE (PEOPLE); VERY ELDERLY; COMPLICATION; DIABETES MELLITUS, TYPE 2; METABOLISM; PROPORTIONAL HAZARDS MODEL; PROSTATIC NEOPLASMS; RISK FACTOR; SWEDEN;

AGED; AGED, 80 AND OVER; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; METFORMIN; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RISK FACTORS; SULFONYLUREA COMPOUNDS; SWEDEN;

EID: 84996629700     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.30480     Document Type: Article

References (50)

1. Fall K, Garmo H, Gudbjornsdottir S, et al. Diabetes mellitus and prostate cancer risk: a nationwide case-control study within PCBaSe Sweden. Cancer Epidemiol Biomarkers Prev 2013;22:1102–09.
2. Bonovas S, Filioussi K, Tsantes A. Diabetes mellitus and risk of prostate cancer: a meta-analysis. Diabetologia 2004;47:1071–78.
3. Kasper J, Giovannucci E. A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2006;15:2056
4. Atchison EA, Gridley G, Carreon JD, et al. Risk of cancer in a large cohort of U.S. veterans with diabetes. Int J Cancer 2011;128:635–43.
5. Walker JJ, Brewster DH, Colhoun HM, et al. Type 2 diabetes, socioeconomic status and risk of cancer in Scotland 2001-2007. Diabetologia 2013;56:1712–5.
6. Tsilidis KK, Kasimis JC, Lopez DS, et al. Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. BMJ 2015;350:g7607
7. Murtola TJ, Tammela TL, Lahtela J, et al. Antidiabetic medication and prostate cancer risk: a population-based case-control study. Am J Epidemiol 2008;168:925–31.
8. Preston MA, Riis AH, Ehrenstein V, et al. Metformin use and prostate cancer risk. Eur Urol 2014;66:1012–20.
9. Tseng CH. Metformin significantly reduces incident prostate cancer risk in Taiwanese men with type 2 diabetes mellitus. Eur J Cancer 2014;50:2831–37.
10. Wright JL, Stanford JL. Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study. Cancer Cause Control 2009;20:1617–22.
11. Margel D, Urbach D, Lipscombe LL, et al. Association between metformin use and risk of prostate cancer and its grade. J Natl Cancer Inst 2013;105:1123–31.
12. Chen YB, Chen Q, Wang Z, et al. Insulin therapy and risk of prostate cancer: a systematic review and meta-analysis of observational studies. PLoS One 2013;8:
13. Karlstad O, Starup-Linde J, Vestergaard P, et al. Use of insulin and insulin analogs and risk of cancer—systematic review and meta-analysis of observational studies. Curr Drug Safety 2013;8:333–48.
14. Tsilidis KK, Capothanassi D, Allen NE, et al. Metformin does not affect cancer risk: a cohort study in the UK clinical practice research datalink analyzed like an intention-to-treat trial. Diabetes Care 2014;37:2522–32.
15. Harding JL, Shaw JE, Peeters A, et al. Cancer risk among people with type 1 and type 2 diabetes: disentangling true associations, detection bias, and reverse causation (vol 38, pg 264, 2015). Diabetes Care 2015;38:734–34.
16. Johnson JA, Bowker SL, Richardson K, et al. Time-varying incidence of cancer after the onset of type 2 diabetes: evidence of potential detection bias. Diabetologia 2011;54:2263–71.
17. Johnson JA, Carstensen B, Witte D, et al. Diabetes and cancer (1): evaluating the temporal relationship between type 2 diabetes and cancer incidence. Diabetologia 2012;55:1607–18.
18. Suissa S, Azoulay L. Metformin and the risk of cancer: time-related biases in observational studies. Diabetes Care 2012;35:2665–73.
19. Van Hemelrijck M, Wigertz A, Sandin F, et al. Cohort profile: The National Prostate Cancer Register of Sweden and Prostate Cancer data Base Sweden 2.0. Int J Epidemiol 2013;42:956–67.
20. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic co-morbidity in longitudinal-studies—development and validation. J Chron Dis 1987;40:373–83.
21. Berglund A, Garmo H, Tishelman C, et al. Comorbidity, treatment and mortality: a population based cohort study of prostate cancer in PCBaSe Sweden. J Urol 2011;185:833–9.
22. Statistics Sweden, Longitudinal integration database for health insurance and labour market studies (LISA by Swedish acronym), http://www.scb.se/lisa-en/Accessed May 5, 2016.
23. The Swedish National Diabetes Register (NDR), Annual report, 2014 https://www.ndr.nu/pdfs/Arsrapport_NDR_2014.pdf Accessed May 5, 2016.
24. Gudbjornsdottir S, Cederholm J, Nilsson PM, et al. The National Diabetes Register in Sweden: an implementation of the St. Vincent Declaration for Quality Improvement in Diabetes Care. Diabetes Care 2003;26:1270–6.
25. White IR, Royston P, Wood AM. Multiple imputation using chained equations: issues and guidance for practice. Stat Med 2011;30:377–99.
26. National Comprehensive Cancer Network, NCCN Guidelines, 2012, http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf Accessed May 5, 2016
27. Jian GP, Mo L, Lu Y, et al. Diabetes mellitus and the risk of prostate cancer: an update and cumulative meta-analysis. Endocr Res 2014;1–8.
28. Waters KM, Henderson BE, Stram DO, et al. Association of diabetes with prostate cancer risk in the multiethnic cohort. Am J Epidemiol 2009;169:937–45.
29. Kasper JS, Liu Y, Giovannucci E. Diabetes mellitus and risk of prostate cancer in the health professionals follow-up study. Int J Cancer 2009;124:1398–403.
30. Leitzmann MF, Ahn J, Albanes D, et al. Diabetes mellitus and prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Causes Control 2008;19:1267–76.
31. Carstensen B, Witte DR, Friis S. Cancer occurrence in Danish diabetic patients: duration and insulin effects. Diabetologia 2012;55:948–58.
32. Rodriguez C, Patel AV, Mondul AM, et al. Diabetes and risk of prostate cancer in a prospective cohort of US men. Am J Epidemiol 2005;161:147–52.
33. Tsilidis KK, Allen N, Travis R, et al. Diabetes mellitus and risk of prostate cancer in the European prospective investigation into cancer and nutrition. Int J Cancer 2015;136:372–81
34. Xu H, Jiang HW, Ding GX, et al. Diabetes mellitus and prostate cancer risk of different grade or stage: a systematic review and meta-analysis. Diabetes Res Clin Pract 2013;99:241–49.
35. Calton BA, Chang SC, Wright ME, et al. History of diabetes mellitus and subsequent prostate cancer risk in the NIH-AARP Diet and Health Study. Cancer Cause Control 2007;18:493–503.
36. Sarma AV, Parsons JK, McVary K, et al. Diabetes and benign prostatic hyperplasia/lower urinary tract symptoms-what do we know?. J Urol 2009;182:S32–S37.
37. Parsons JK. Benign prostatic hyperplasia and male lower urinary tract symptoms: epidemiology and risk factors. Curr Bladder Dysfunct Rep 2010;5:212–18.
38. Barry MJ, Fowler FJ, Jr, O'Leary MP, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 1992;148:1549–57.
39. Rohrmann S, Smit E, Giovannucci E, et al. Association between markers of the metabolic syndrome and lower urinary tract symptoms in the Third National Health and Nutrition Examination Survey (NHANES III). Int J Obes (Lond) 2005;29:310–16.
40. Feng T, Sun X, Howard LE, et al. Metformin use and risk of prostate cancer: results from the REDUCE study. Cancer Prev Res (Phila) 2015;8:1055–60.
41. Azoulay L, Dell'Aniello S, Gagnon B, et al. Metformin and the incidence of prostate cancer in patients with type 2 diabetes. Cancer Epidemiol Biomarkers Prev 2011;20:337–44.
42. Noto H, Goto A, Tsujimoto T, et al. Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS One 2012;7:e33411
43. Franciosi M, Lucisano G, Lapice E, et al. Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. PLoS One 2013;8:e71583
44. Soranna D, Scotti L, Zambon BC, et al. Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis. Oncologist 2012;17:813–22.
45. Rastmanesh R, Hejazi J, Marotta F, et al. Type 2 diabetes: a protective factor for prostate cancer? An overview of proposed mechanisms. Clin Genitourin Cancer 2014;12:143–8.
46. Pierce BL, Ahsan H. Genetic susceptibility to type 2 diabetes is associated with reduced prostate cancer risk. Hum Hered 2010;69:193–201.
47. Pierce BL. Why are diabetics at reduced risk for prostate cancer? A review of the epidemiologic evidence. Urol Oncol 2012;30:735–43.
48. Carstensen B, Jorgensen ME, Friis S. The epidemiology of diabetes and cancer. Curr Diab Rep 2014;14:535
49. Ekstrom N, Miftaraj M, Svensson AM, et al. Glucose-lowering treatment and clinical results in 163 121 patients with type 2 diabetes: an observational study from the Swedish national diabetes register. Diabetes Obes Metab 2012;14:717–26.
50. Stocks T, Lukanova A, Rinaldi S, et al. Insulin resistance is inversely related to prostate cancer: a prospective study in Northern Sweden. Int J Cancer 2007; 120:2678–86.